Jimin Health insiders to sell 5% stake for $24M to two-month-old buyer
What's the deal? Jimin Health's controlling shareholder, Shuangge Group, and actual controller Zhang Xueqin have agreed to sell 26.26 million shares — 5% of the company — to Luzhou Jinke Qi Chuangxin, a limited partnership. The price is US$0.84 per share, or about US$22M (≈$24 million). The Shanghai-listed Chinese firm disclosed the agreement on November 4.
What changes? The sale does not trigger a tender offer or shift control; Jinke Qi Chuangxin becomes a 5% shareholder with a 12-month lock-up. Jimin Health says the sellers acted on their own "funding needs," while the buyer values the company's long-term prospects. The deal still needs Shanghai Stock Exchange confirmation and share-transfer registration.
Why the scrutiny? The buyer was formed only on September 2, 2026, roughly two months before signing. Its managing partner, Chengdu Ruihe, posted a 2025 net loss of US$155.4K and held net assets of just US$1.22M at mid-2026.
Unusual terms: The final 60% of payment — about US$13.2M — falls due only after the shares transfer to the buyer, reversing the common A-share practice of collecting most funds first. The agreement also cedes jurisdiction for disputes to courts in the buyer's home city, Luzhou, though Jimin Health is based in Taizhou, Zhejiang.
The company's answer: Jimin Health said the buyer's registered capital is US$37.1M, all self-funded, and that one major backer — Sichuan Jinduo Investment — is a subsidiary of Luzhou Laojiao Group, ultimately controlled by Luzhou's state asset regulator. On the payment and jurisdiction clauses, it said only that "the specific transaction terms are the result of negotiations between the two parties."
The backdrop: The transfer prices the shares at a roughly 10% discount to the prior day's US$0.93 close. It lands as Jimin Health's first-three-quarter 2026 revenue fell 8.6% year over year to US$68.5M, and its net loss widened to US$11.3M.
The signal: With no strategic shift involved, the story turns on execution and counterparty risk — whether a thinly capitalised, newly formed buyer can pay, and why the sellers accepted terms that leave them more exposed than usual.
Read more: sohu.com
Image credit: jimin health
